BioAge Labs Inc. Financials
BioAge Labs Inc. (BIOA) reported $10.4M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioAge’s dominant mechanic is development-stage spending: research investment greatly exceeds revenue while losses convert almost directly into cash use.
R&D spending rose from$33.9M in FY2023 to$74.0M in FY2025, showing that resources have increasingly been directed toward development. That investment coincided with operating cash outflow widening from-$37.4M to-$81.6M , so the business has not yet produced operating self-funding.
FY2025 revenue was
Financing inflow fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioAge Labs Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioAge Labs Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Not available for BioAge Labs Inc., and counted as zero in the overall score.
BioAge Labs Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 14.24, BioAge Labs Inc. holds $14.24 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.
BioAge Labs Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
BioAge Labs Inc. posts a -29.6% return on equity (ROE), meaning it loses $30 for every $100 of shareholders' equity. This results in a returns score of 11/100. This is down from -22.0% the prior year.
BioAge Labs Inc. scores 10.13, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($442.9M) relative to total liabilities ($22.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioAge Labs Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
BioAge Labs Inc. reported a net loss of $80.6M while operations used $81.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BioAge Labs Inc. reported an operating loss of $92.8M against $697K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BioAge Labs Inc. generated $9.0M in revenue in fiscal year 2025.
BioAge Labs Inc.'s EBITDA was -$92.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.7% from the prior year.
BioAge Labs Inc. reported -$80.6M in net income in fiscal year 2025. This represents a decrease of 13.4% from the prior year.
Cash & Balance Sheet
BioAge Labs Inc. recorded an outflow of $82.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 58.7% from the prior year.
BioAge Labs Inc. held $188.9M in cash against $0 in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
BioAge Labs Inc.'s ROE was -29.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 7.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BioAge Labs Inc. invested $74.0M in research and development in fiscal year 2025. This represents an increase of 25.3% from the prior year.
BioAge Labs Inc. invested $719K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 96.4% from the prior year.
Not reported for fiscal year 2025.
BIOA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M-11.6% | $2.8M-9.9% | $3.1M+49.9% | $2.1M-14.8% | $2.4M+66.2% | $1.5M | N/A | $0 |
| R&D Expenses | $24.4M+19.4% | $20.4M-16.7% | $24.5M+32.3% | $18.5M-6.7% | $19.8M+78.6% | $11.1M | N/A | $20.0M |
| SG&A Expenses | $7.4M-4.1% | $7.7M+10.5% | $7.0M+4.8% | $6.7M-9.0% | $7.3M+8.1% | $6.8M | N/A | $4.7M |
| Operating Income | -$29.3M-15.6% | -$25.4M+10.7% | -$28.4M-22.8% | -$23.1M+6.6% | -$24.8M-50.6% | -$16.4M | N/A | -$24.8M |
| Interest Expense | $1K-97.4% | $39K-57.6% | $92K-38.3% | $149K-25.9% | $201K-21.2% | $255K | N/A | $388K |
| Net Income | -$26.1M-17.3% | -$22.3M+14.2% | -$25.9M-28.6% | -$20.2M+6.5% | -$21.6M-66.8% | -$12.9M | N/A | -$23.4M |
| EPS (Diluted) | -$0.58-11.5% | -$0.52+27.8% | -$0.72-28.6% | -$0.56+6.7% | -$0.60-66.7% | -$0.36-102.4% | $15.13+325.8% | -$6.70 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
BIOA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $396.9M-0.2% | $397.7M+34.8% | $294.9M-3.3% | $305.1M-5.3% | $322.1M-6.3% | $343.8M-4.0% | $358.2M+6.2% | $337.4M |
| Current Assets | $330.3M-15.7% | $391.9M+36.6% | $286.8M-1.4% | $290.8M-3.6% | $301.7M-7.1% | $324.8M-9.0% | $357.1M+6.1% | $336.5M |
| Cash & Equivalents | $74.0M-69.4% | $241.8M+28.0% | $188.9M-12.4% | $215.6M-2.2% | $220.3M-14.4% | $257.5M-27.3% | $354.3M+5.9% | $334.5M |
| Accounts Receivable | $625K-11.8% | $709K-7.8% | $769K+49.3% | $515K-14.6% | $603K+67.0% | $361K | $0 | N/A |
| Total Liabilities | $22.0M+18.8% | $18.5M-18.9% | $22.8M-17.3% | $27.6M+0.9% | $27.4M-10.8% | $30.7M-12.6% | $35.1M+48.6% | $23.6M |
| Current Liabilities | $19.2M+21.4% | $15.8M-21.4% | $20.1M-17.8% | $24.5M+7.3% | $22.8M-3.8% | $23.7M-14.5% | $27.8M+45.6% | $19.1M |
| Long-Term Debt | N/A | N/A | $0 | $0 | $0-100.0% | $1.1M-57.8% | $2.5M-36.5% | $3.9M |
| Total Equity | $374.9M-1.1% | $379.1M+39.4% | $272.1M-2.0% | $277.5M-5.9% | $294.8M-5.9% | $313.2M-3.1% | $323.1M+3.0% | $313.7M |
| Retained Earnings | -$381.8M-7.3% | -$355.7M-6.7% | -$333.4M-8.4% | -$307.5M-7.0% | -$287.3M-8.1% | -$265.7M-5.1% | -$252.8M-9.1% | -$231.7M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
BIOA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.3M+19.9% | -$24.0M+14.9% | -$28.3M-76.1% | -$16.0M+19.7% | -$20.0M-15.0% | -$17.4M-237.9% | -$5.1M+65.6% | -$14.9M |
| Capital Expenditures | $328K+1161.5% | $26K-76.8% | $112K+409.1% | $22K-86.2% | $159K-62.7% | $426K+1538.5% | $26K-91.5% | $305K |
| Free Cash Flow | -$19.6M+18.6% | -$24.1M+15.1% | -$28.4M-76.5% | -$16.1M+20.2% | -$20.1M-13.1% | -$17.8M-244.5% | -$5.2M+66.1% | -$15.2M |
| Investing Cash Flow | -$164.5M-251.9% | -$46.8M-224.0% | -$14.4M-212.4% | $12.8M+182.1% | -$15.6M+79.9% | -$78.0M-299853.8% | -$26K+91.5% | -$305K |
| Financing Cash Flow | $16.0M-87.1% | $123.7M+672.6% | $16.0M+1137.1% | -$1.5M-2.9% | -$1.5M0.0% | -$1.5M-106.0% | $24.9M-86.9% | $190.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIOA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1196.8% | -915.4% | -923.4% | -1126.6% | -1027.0% | -1133.4% | N/A | N/A |
| Net Margin | -1064.8% | -802.8% | -842.8% | -982.0% | -894.0% | -891.0% | N/A | N/A |
| Return on Equity | -7.0%-1.1pp | -5.9%+3.7pp | -9.5%-2.3pp | -7.3%0.0pp | -7.3%-3.2pp | -4.1% | N/A | -7.5% |
| Return on Assets | -6.6%-1.0pp | -5.6%+3.2pp | -8.8%-2.2pp | -6.6%+0.1pp | -6.7%-2.9pp | -3.8% | N/A | -6.9% |
| Current Ratio | 17.19-7.6x | 24.76+10.5x | 14.24+2.4x | 11.87-1.3x | 13.21-0.5x | 13.68+0.8x | 12.86-4.8x | 17.63 |
| Debt-to-Equity | 0.060.0x | 0.050.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.01 |
| FCF Margin | -799.2% | -868.4% | -921.5% | -782.2% | -834.5% | -1226.0% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where BioAge Labs Inc. Ranks
Frequently Asked Questions
What is BioAge Labs Inc.'s annual revenue?
BioAge Labs Inc. (BIOA) reported $9.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is BioAge Labs Inc. profitable?
No, BioAge Labs Inc. (BIOA) reported a net income of -$80.6M in fiscal year 2025.
What is BioAge Labs Inc.'s EBITDA?
BioAge Labs Inc. (BIOA) had EBITDA of -$92.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioAge Labs Inc. have?
As of fiscal year 2025, BioAge Labs Inc. (BIOA) had $188.9M in cash and equivalents against $0 in long-term debt.
What is BioAge Labs Inc.'s return on equity (ROE)?
BioAge Labs Inc. (BIOA) has a return on equity of -29.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioAge Labs Inc.'s free cash flow?
BioAge Labs Inc. (BIOA) recorded an outflow of $82.3M in free cash flow during fiscal year 2025. This represents a -58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioAge Labs Inc.'s operating cash flow?
BioAge Labs Inc. (BIOA) recorded an outflow of $81.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioAge Labs Inc.'s total assets?
BioAge Labs Inc. (BIOA) had $294.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioAge Labs Inc.'s capital expenditures?
BioAge Labs Inc. (BIOA) invested $719K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioAge Labs Inc. spend on research and development?
BioAge Labs Inc. (BIOA) invested $74.0M in research and development during fiscal year 2025.
What is BioAge Labs Inc.'s current ratio?
BioAge Labs Inc. (BIOA) had a current ratio of 14.24 as of fiscal year 2025, which is generally considered healthy.
What is BioAge Labs Inc.'s debt-to-equity ratio?
BioAge Labs Inc. (BIOA) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioAge Labs Inc.'s return on assets (ROA)?
BioAge Labs Inc. (BIOA) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does BioAge Labs Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BioAge Labs Inc. (BIOA) held $285.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $81.6M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BioAge Labs Inc.'s Altman Z-Score?
BioAge Labs Inc. (BIOA) has an Altman Z-Score of 10.13, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioAge Labs Inc.'s Piotroski F-Score?
BioAge Labs Inc. (BIOA) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioAge Labs Inc.'s earnings high quality?
BioAge Labs Inc. (BIOA) reported a net loss of $80.6M while operations used $81.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioAge Labs Inc. cover its interest payments?
BioAge Labs Inc. (BIOA) reported an operating loss of $92.8M against $697K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioAge Labs Inc.?
BioAge Labs Inc. (BIOA) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.